バイオテクノロジーにおけるAI市場規模、シェア、動向、2035年までの世界予測

バイオテクノロジーにおけるAI市場- 機能（医薬品設計・最適化、バイオマーカー、SAR、臨床試験設計、データ評価、RWE、在庫、サプライチェーン、物流、発売、価格設定、患者エンゲージメント、有害事象）およびエンドユーザー – 2035年までの世界予測

バイオテクノロジーにおけるAI活用の世界市場は、2025年の41億5,690万米ドルから2035年には227億1,650万米ドルに達し、予測期間中は年平均成長率（CAGR）18.5%で成長すると予測されています。市場は着実に成長しており、その牽引役として、医薬品の安全性と有効性に関する予測分析へのAI導入の増加、実験室プロセスにおけるAIを活用した自動化の活用拡大、そしてコスト効率が高く加速する研究パイプラインへの需要の高まりが挙げられます。さらに、大規模な生物学的データセットの利用拡大、クラウドコンピューティング基盤の進歩、そしてライフサイエンス分野におけるAI活用を促進する政府の支援策も、市場の成長を後押ししています。AIと新興バイオテクノロジーの融合により、イノベーションの加速、意思決定の改善、そしてよりパーソナライズされたヘルスケアソリューションが実現しています。

本レポートは、バイオテクノロジーにおけるAI市場を分析し、提供内容、機能、導入形態、エンドユーザー、地域に基づいて、様々な市場セグメントの市場規模と将来の成長ポテンシャルを推定することを目的としています。また、この市場で活動する主要企業の競合分析に加え、各社の企業概要、製品ラインナップ、最近の動向、主要な市場戦略についても解説しています。

このレポートは、既存企業だけでなく、新規参入企業や中小企業にとっても、市場の動向を把握し、市場シェアの拡大に役立てることができます。本レポートを購入した企業は、以下の戦略のいずれか、または組み合わせて活用することで、市場における地位を強化することができます。

本レポートは、以下の点について洞察を提供します。

バイオテクノロジーにおけるAI市場の成長に影響を与える主要な推進要因（業種横断的なコラボレーションとパートナーシップの拡大、創薬・開発にかかる時間とコストの削減ニーズの高まり、精密医療におけるAI導入の増加、コンピューティング能力の向上とハードウェアコストの低下）、制約要因（AI導入コストの高さが、特に中小企業や新興国におけるバイオテクノロジーへのAI導入を阻害している）、バイオテクノロジーにおけるAIのデータプライバシーリスクとコンプライアンス上の課題）、機会（バイオテクノロジーの発展に向けた精密医療におけるAIとビッグデータの統合、バイオテクノロジー投資の急増によるAIによる創薬イノベーションの加速機会の拡大、ヘルスケア、農業、環境科学分野におけるイノベーションによる世界的な成長）、課題（AIの統合と信頼性を阻害するデータ品質と解釈可能性の問題、人材不足と変化する規制上の課題によってバイオテクノロジーにおけるAIの導入が阻害されている）の分析

• 製品開発／イノベーション：AI in Biotechnology市場における今後の技術、研究開発活動、新製品・サービス投入に関する詳細な洞察
• 市場開発：収益性の高い新興市場、提供内容、機能、導入形態、エンドユーザー、地域に関する包括的な情報
• 市場多様化：AI in Biotechnology市場における製品ポートフォリオ、成長地域、最近の開発状況、投資に関する網羅的な情報
• 競合評価：NVIDIA（米国）、Illumina, Inc.（米国）、Recursion（米国）、Schrödinger Inc.（米国）、BenevolentAI（英国）など、AI in Biotechnology市場の主要プレーヤーの市場シェア、成長戦略、製品提供、および能力に関する詳細な評価

Report Description

The global AI in biotechnology market is projected to reach USD 22,716.5 million by 2035 from USD 4,156.9 million in 2025, at a high CAGR of 18.5% during the forecast period. The market is progressing steadily, driven by the growing adoption of AI for predictive analytics in drug safety and efficacy, the increasing use of AI-powered automation in laboratory processes, and the rising demand for cost-efficient and accelerated research pipelines. Moreover, the expanding availability of large-scale biological datasets, advancements in cloud computing infrastructure, and supportive government initiatives promoting AI in life sciences further propel market growth. The convergence of AI with emerging biotechnologies is enabling faster innovation, improved decision-making, and more personalized healthcare solutions.

“The research & development segment of the AI in biotechnology market is the largest segment during the forecast period.”

Based on function, the research & development (R&D) segment accounted for the largest share of the AI in biotechnology market and is projected to maintain its lead in the coming years. This dominance is driven by the increasing use of AI to accelerate drug discovery, optimize molecular design, and predict compound efficacy and safety. AI-powered tools enable researchers to analyze large-scale genomic, proteomic, and clinical datasets more efficiently, reducing experimental timelines and costs. Additionally, the integration of machine learning algorithms with high-throughput screening and automated laboratory platforms is enhancing the precision and scalability of R&D processes. As biotech companies strive to bring novel therapeutics to market faster, the adoption of AI in R&D continues to be a key growth driver.

“Based on the end user, the pharmaceutical companies segment accounted for the largest share of AI in biotechnology market during the forecast period.”

The pharmaceutical companies segment accounted for the largest share of the AI in biotechnology market during the forecast period. This growth is driven by the increasing adoption of AI for accelerating drug discovery, optimizing clinical trial design, and predicting drug efficacy and safety profiles. Pharmaceutical firms are leveraging AI to analyze large-scale biological and clinical datasets, identify novel drug targets, and streamline R&D workflows, reducing time and cost. Additionally, AI-enabled predictive modeling and virtual screening tools help companies make data-driven decisions, enhance success rates, and bring new therapies to market more efficiently. The rising demand for personalized medicine and the pressure to innovate rapidly further reinforce the adoption of AI within the pharmaceutical sector.

“Asia Pacific is projected to witness the highest growth rate during the forecast period.”

The Asia Pacific region is projected to witness the highest growth rate in the AI in biotechnology market during the forecast period. This rapid expansion is driven by a strong focus on technological advancement and research excellence. Countries across the region are strengthening their innovation ecosystems through enhanced infrastructure, academic-industry partnerships, and cross-border collaborations. The growing emphasis on precision medicine, data-driven healthcare, and sustainable biomanufacturing is also creating new opportunities for market development. Moreover, supportive regulatory frameworks and increasing public-private initiatives position Asia Pacific as a global hub for next-generation biotechnological progress.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the AI in biotechnology marketplace. The breakdown of primary participants is as mentioned below:

• By Company Type – Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
• By Designation – C-Level: 35%, Director Level: 25%, and Others: 40%
• By Region – North America: 30%, Europe: 45%, Asia Pacific: 20%, Latin America: 3%, Middle East & Africa: 2%

Key Players in the AI in Biotechnology Market

The key players operating in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India).

Research Coverage

The report analyzes the AI in biotechnology market and aims to estimate the market size and future growth potential of various market segments, based on offering, function, deployment mode, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights into the following:

Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth) challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in biotechnology market
• Market Development: Comprehensive information on the lucrative emerging markets, offering, function, deployment mode, end user, and region
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology  market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market, like NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger Inc. (US), and BenevolentAI (UK)

Table of Contents

1               INTRODUCTION              53

1.1           STUDY OBJECTIVES       53

1.2           MARKET DEFINITION   53

1.3           STUDY SCOPE   54

1.3.1        MARKETS COVERED & REGIONAL SCOPE             54

1.3.2        INCLUSIONS & EXCLUSIONS       55

1.3.3        YEARS CONSIDERED      56

1.3.4        CURRENCY CONSIDERED            57

1.4           RESEARCH LIMITATIONS             57

1.5           STAKEHOLDERS               58

2               RESEARCH METHODOLOGY       59

2.1           RESEARCH DATA              59

2.1.1        SECONDARY DATA          60

2.1.1.1    Key data from secondary sources       61

2.1.2        PRIMARY DATA 61

2.1.2.1    Key data from primary sources           63

2.1.2.2    Insights from primary experts             64

2.2           MARKET SIZE ESTIMATION         65

2.3           DATA TRIANGULATION                69

2.4           MARKET SHARE ESTIMATION    69

2.5           RESEARCH ASSUMPTIONS           70

2.6           RESEARCH LIMITATIONS             70

2.6.1        METHODOLOGY-RELATED LIMITATIONS           70

2.6.2        SCOPE-RELATED LIMITATIONS                 70

2.7           RISK ASSESSMENT           71

3               EXECUTIVE SUMMARY  72

4               PREMIUM INSIGHTS       76

4.1           AI IN BIOTECHNOLOGY MARKET OVERVIEW     76

4.2           AI IN BIOTECHNOLOGY MARKET, BY REGION   77

4.3           NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING AND COUNTRY           78

4.4           AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT          79

4.5           AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES               79

5               MARKET OVERVIEW       80

5.1           INTRODUCTION              80

5.2           MARKET DYNAMICS       80

5.2.1        DRIVERS               82

5.2.1.1    Growing cross-industry collaborations and partnerships                 82

5.2.1.2    Increasing need to reduce time and cost of drug discovery & development          83

5.2.1.3    Rising adoption of AI in precision medicine    84

5.2.1.4    Increasing investments in semiconductor chipsets         85

5.2.2        RESTRAINTS      85

5.2.2.1    High implementation costs 85

5.2.2.2    Data privacy risks and compliance challenges 85

5.2.3        OPPORTUNITIES              86

5.2.3.1    Rise of advanced analytics and predictive modeling       86

5.2.3.2    Surge in biotechnology investments  87

5.2.3.3    Innovations across healthcare, agriculture, and environmental science   87

5.2.4        CHALLENGES    88

5.2.4.1    Data quality and interpretability issues             88

5.2.4.2    Shortage of qualified experts and evolving regulatory challenges                 88

5.3           UNMET NEEDS AND WHITE SPACES       89

5.4           INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES              90

5.5           STRATEGIC MOVES BY TIER 1/2/3 PLAYERS         91

6               INDUSTRY TRENDS         92

6.1           EVOLUTION OF AI IN BIOTECHNOLOGY              92

6.2           PORTER’S FIVE FORCES ANALYSIS           94

6.2.1        BARGAINING POWER OF SUPPLIERS       95

6.2.2        BARGAINING POWER OF BUYERS             95

6.2.3        THREAT OF SUBSTITUTES          95

6.2.4        THREAT OF NEW ENTRANTS      95

6.2.5        INTENSITY OF COMPETITIVE RIVALRY 95

6.3           MACROECONOMICS INDICATORS           95

6.3.1        INTRODUCTION              95

6.3.2        GDP TRENDS AND FORECAST   96

6.3.3        TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY                 96

6.4           VALUE CHAIN ANALYSIS               96

6.5           ECOSYSTEM ANALYSIS  97

6.6           PRICING ANALYSIS          100

6.6.1        INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING,

BY KEY PLAYERS (2024) 100

6.6.2        INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION                101

6.7           KEY CONFERENCES AND EVENTS, 2025–2026        101

6.8           TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       102

6.9           INVESTMENT AND FUNDING SCENARIO               103

6.10         CASE STUDY ANALYSIS 103

6.10.1      CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD        103

6.10.2      CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION                 104

6.10.3      CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS          104

6.11         IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET               105

6.11.1      INTRODUCTION              105

6.11.2      KEY TARIFF RATES          105

6.11.3      PRICE IMPACT ANALYSIS             106

6.11.4      IMPACT ON COUNTRIES/REGIONS         106

6.11.4.1  North America      106

6.11.4.2  Europe   107

6.11.4.3  Asia Pacific            107

6.11.5      IMPACT ON END-USE INDUSTRIES          107

6.11.5.1  Pharmaceutical companies 107

6.11.5.2  Biotechnology companies   107

6.11.5.3  Research institutes and labs                108

6.11.5.4  Healthcare providers            108

6.11.5.5  Contract Research Organizations (CROs)       108

7               STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,

AND AI ADOPTIONS       109

7.1           KEY EMERGING TECHNOLOGIES              109

7.1.1        NATURAL LANGUAGE PROCESSING (NLP)           109

7.1.2        PREDICTIVE ANALYTICS               109

7.2           COMPLEMENTARY TECHNOLOGIES       109

7.2.1        CLOUD COMPUTING     109

7.2.2        BIG DATA ANALYTICS   109

7.3           TECHNOLOGY/PRODUCT ROADMAP    110

7.4           PATENT ANALYSIS          111

7.4.1        PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY           111

7.4.2        JURISDICTION AND TOP APPLICANT ANALYSIS                 111

7.5           FUTURE APPLICATIONS               116

7.5.1        AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION   116

7.5.2        GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS            117

7.6           IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET               117

7.6.1        INTRODUCTION              117

7.6.2        TOP USE CASES AND MARKET POTENTIAL          118

7.6.3        INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS  119

7.6.3.1    Drug discovery and development market         119

7.6.3.2    Genomics and bioinformatics market                120

7.6.3.3    Medical imaging & diagnostics market              120

7.6.4        CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET  120

7.6.4.1    User readiness       120

7.6.4.1.1 Pharmaceutical companies 120

7.6.4.1.2 Biotechnology companies   120

7.6.4.2    Impact assessment                121

7.6.4.2.1 User A: Pharmaceutical companies   121

7.6.4.2.1.1              Implementation    121

7.6.4.2.1.2              Impact    121

7.6.4.2.2 User B: Biotechnology companies     121

7.6.4.2.2.1              Implementation    121

7.6.4.2.2.2              Impact    122

7.6.5        CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION                 122

7.6.5.1    Case Study 1: Enhanced operations and revenue using AI-driven real-world data analytics     122

7.6.5.2    Case study 2: Advance AI-powered target discovery with proprietary AI platform       123

8               REGULATORY LANDSCAPE         124

8.1           REGIONAL REGULATIONS AND COMPLIANCE   124

8.1.1        NORTH AMERICA             124

8.1.2        EUROPE               125

8.1.3        ASIA PACIFIC     126

8.1.4        LATIN AMERICA                127

8.1.5        MIDDLE EAST & AFRICA                127

8.2           REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             128

8.3           INDUSTRY STANDARDS                130

9               CUSTOMER LANDSCAPE & BUYER BEHAVIOR    131

9.1           DECISION-MAKING PROCESS     131

9.2           INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA                 131

9.2.1        BUYING CRITERIA           132

9.3           ADOPTION BARRIERS AND INTERNAL CHALLENGES                 133

9.4           UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES                 133

9.5           END-USER EXPECTATIONS         134

10            AI IN BIOTECHNOLOGY MARKET, BY OFFERING                 135

10.1         INTRODUCTION              136

10.2         END-TO-END SOLUTIONS           137

10.2.1      GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH             137

10.3         NICHE SOLUTIONS         138

10.3.1      ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION         138

10.4         TECHNOLOGIES               139

10.4.1      ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH          139

10.5         SERVICES             141

10.5.1      CONSULTING SERVICES                142

10.5.1.1  Increasing efficiency of research processes and cost savings to boost adoption      142

10.5.2      IMPLEMENTATION SERVICES & ONGOING IT SUPPORT                 143

10.5.2.1  Increasing precision and efficiency in IT support services to boost demand  143

10.5.3      TRAINING & EDUCATION SERVICES        144

10.5.3.1  Need for skilled talent for better training & education services to drive market          144

10.5.4      POST-SALES & MAINTENANCE SERVICES              145

10.5.4.1  Complexity of AI systems and need for improvement in AI algorithms to boost market 145

11            AI IN BIOTECHNOLOGY MARKET, BY FUNCTION                 147

11.1         INTRODUCTION              148

11.2         RESEARCH & DEVELOPMENT    149

11.2.1      DRUG DISCOVERY           151

11.2.1.1  Molecular design & optimization       153

11.2.1.1.1                Increased efficiency in drug discovery with molecular design & optimization to drive market              153

11.2.1.2  Biomarker discovery             154

11.2.1.2.1                Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand               154

11.2.1.3  Structure-activity relationship (SAR) modeling              155

11.2.1.3.1                Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth                 155

11.2.2      CLINICAL DEVELOPMENT           156

11.2.2.1  Trial design           158

11.2.2.1.1                Ability of AI to improve trial design through simulations and patient stratification to favor market         158

11.2.2.2  Site selection         159

11.2.2.2.1                Optimized process of selecting clinical trial sites to fuel growth    159

11.2.2.3  Recruitment           160

11.2.2.3.1                Enhanced process of selecting and enrolling participants for clinical trials to drive demand      160

11.2.2.4  Clinical data assessment      161

11.2.2.4.1                Ability of clinical data assessment for efficient and accurate of data interpretation to propel market             161

11.2.2.5  Predictive toxicity & risk monitoring 162

11.2.2.5.1                Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates 162

11.2.2.6  Monitoring & drug adherence            163

11.2.2.6.1                Enhanced patient compliance with monitoring and drug adherence to drive market  163

11.2.2.7  Real-world evidence (RWE) analysis                 164

11.2.2.7.1                Enhanced safety monitoring and economic evaluation with RWE analysis to propel growth 164

11.3         REGULATORY COMPLIANCE      165

11.3.1      ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH      165

11.4         MANUFACTURING & SUPPLY CHAIN       166

11.4.1      SUPPLY CHAIN PLANNING          168

11.4.1.1  Increasing demand for real-time data analytics to accelerate market growth       168

11.4.2      INVENTORY MANAGEMENT       169

11.4.2.1  Automating stock tracking and replenishment with advanced analytics to fuel market growth           169

11.4.3      LOGISTICS OPTIMIZATION         170

11.4.3.1  Ability of AI for increased collaboration and transparency in biotechnology logistics to aid growth                 170

11.4.4      DEMAND FORECASTING              171

11.4.4.1  Ability to integrate data for a reliable demand forecast to fuel market growth       171

11.4.5      PREDICTIVE MAINTENANCE      172

11.4.5.1  Boosting equipment reliability with AI-powered predictive maintenance to drive demand            172

11.4.6      OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS       173

11.5         LAUNCH & COMMERCIAL             174

11.5.1      LAUNCH COORDINATION           176

11.5.1.1  Increasing product launch success rates through predictive analytics to boost adoption 176

11.5.2      PATIENT ENGAGEMENT               177

11.5.2.1  Real-time patient feedback for better health outcomes to support growth    177

11.5.3      MARKETING OPERATIONS          178

11.5.3.1  Enhanced marketing performance with AI to boost market growth    178

11.5.4      PREDICTIVE PRICING    179

11.5.4.1  Ability of AI to enhance pricing accuracy to drive adoption                 179

11.6         POST-MARKETING SURVEILLANCE & PATIENT SUPPORT             180

11.6.1      MEDICATION ADHERENCE         182

11.6.1.1  Growing demand for personalized treatment plans to drive market    182

11.6.2      ADVERSE EVENT REPORTING    184

11.6.2.1  Faster post-market surveillance and enhanced drug safety to drive demand        184

11.6.3      PATIENT MONITORING                185

11.6.3.1  Rise of remote healthcare solutions to boost market demand                 185

11.6.4      COMPLIANCE MONITORING      186

11.6.4.1  Increasing complexity of regulatory requirements to drive adoption 186

11.6.5      PATIENT SUPPORT PROGRAMS                 187

11.6.5.1  Growing interest in patient-centered care to support market growth    187

11.7         CORPORATE      188

11.7.1      RISK MANAGEMENT       189

11.7.1.1  Rising expenditure for drug development to support growth                 189

11.7.2      COMPLIANCE MONITORING      190

11.7.2.1  Strict guidelines for complex regulatory landscapes to aid market growth    190

11.7.3      SALES FORCE OPTIMIZATION   191

11.7.3.1  Need for data-driven decision-making to boost adoption of sales force optimization                 191

11.7.4      OTHER CORPORATE FUNCTIONS            192

12            AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE   194

12.1         INTRODUCTION              195

12.2         CLOUD-BASED SOLUTIONS        195

12.2.1      PUBLIC CLOUD 197

12.2.1.1  Need to reduce dependency on expensive on-premises infrastructure to boost demand          197

12.2.2      PRIVATE CLOUD              198

12.2.2.1  Need for enhanced security and data protection to propel market growth    198

12.2.3      MULTI-CLOUD 199

12.2.3.1  Enhanced flexibility and cost optimization to support market growth    199

12.2.4      HYBRID CLOUD                201

12.2.4.1  Cost efficiency and flexibility of hybrid cloud models to fuel market growth       201

12.3         ON-PREMISES SOLUTIONS          202

12.3.1      BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH          202

13            AI IN BIOTECHNOLOGY MARKET, BY END USER                 204

13.1         INTRODUCTION              205

13.2         PHARMACEUTICAL COMPANIES               206

13.2.1      INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION                 206

13.3         BIOTECHNOLOGY COMPANIES 207

13.3.1      ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH     207

13.4         RESEARCH INSTITUTES & LABS 208

13.4.1      STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS      208

13.5         HEALTHCARE PROVIDERS           210

13.5.1      IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION         210

13.6         CONTRACT RESEARCH ORGANIZATIONS             211

13.6.1      ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 211

14            AI IN BIOTECHNOLOGY MARKET, BY REGION   213

14.1         INTRODUCTION              214

14.2         NORTH AMERICA             215

14.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 227

14.2.2      US           227

14.2.2.1  US to dominate North American AI in biotechnology market during study period              227

14.2.3      CANADA               238

14.2.3.1  Availability of advanced facilities and shorter approval times for drug candidates to drive market         238

14.3         EUROPE               249

14.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      261

14.3.2      GERMANY           261

14.3.2.1  Increased funding in startups to drive uptake of AI in biotechnology        261

14.3.3      UK          272

14.3.3.1  Increasing investments and government fund allocations to drive market    272

14.3.4      FRANCE                283

14.3.4.1  Government initiatives in France to support market growth                 283

14.3.5      ITALY    294

14.3.5.1  Growing investments to create opportunities for market growth                 294

14.3.6      SPAIN    305

14.3.6.1  Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market                305

14.3.7      REST OF EUROPE             316

14.4         ASIA PACIFIC     327

14.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 340

14.4.2      JAPAN   340

14.4.2.1  Accelerating AI-driven drug discovery and biotechnology innovation to drive Japanese market 340

14.4.3      CHINA  351

14.4.3.1  Rising foreign investments in biotechnology and biopharmaceuticals to propel market growth   351

14.4.4      INDIA    362

14.4.4.1  Increasing number of startups and growing support from government to propel market growth                362

14.4.5      SOUTH KOREA  373

14.4.5.1  Significant advances in AI integration for R&D to fuel growth                 373

14.4.6      AUSTRALIA         384

14.4.6.1  Accelerating AI adoption in Australia’s biotech sector to augment market growth       384

14.4.7      REST OF ASIA PACIFIC   395

14.5         LATIN AMERICA                406

14.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 418

14.5.2      BRAZIL 418

14.5.2.1  Funding of biotech companies to drive Brazilian market growth                 418

14.5.3      MEXICO                429

14.5.3.1  Investment inflows and strengthening AI-related education to spur market growth              429

14.5.4      REST OF LATIN AMERICA             440

14.6         MIDDLE EAST & AFRICA                451

14.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 463

14.6.2      GCC COUNTRIES              463

14.6.2.1  Increase in healthcare investments to support market growth                 463

14.6.3      REST OF MIDDLE EAST & AFRICA             475

15            COMPETITIVE LANDSCAPE         487

15.1         INTRODUCTION              487

15.2         KEY PLAYER STRATEGY/RIGHT TO WIN                487

15.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET  487

15.3         REVENUE ANALYSIS, 2020–2024  490

15.4         MARKET SHARE ANALYSIS, 2024                 490

15.4.1      RANKING OF KEY MARKET PLAYERS       493

15.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 493

15.5.1      STARS   493

15.5.2      EMERGING LEADERS     493

15.5.3      PERVASIVE PLAYERS      494

15.5.4      PARTICIPANTS 494

15.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         495

15.5.5.1  Company footprint               495

15.5.5.2  Region footprint   496

15.5.5.3  Component footprint           497

15.5.5.4  Function footprint                498

15.5.5.5  End-user footprint                499

15.6         COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023        500

15.6.1      PROGRESSIVE COMPANIES         500

15.6.2      RESPONSIVE COMPANIES            500

15.6.3      DYNAMIC COMPANIES  500

15.6.4      STARTING BLOCKS         500

15.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 502

15.6.5.1  Detailed list of key startups/SMEs    502

15.6.5.2  Competitive benchmarking of key startups/SME players                 503

15.7         COMPANY VALUATION & FINANCIAL METRICS 504

15.7.1      FINANCIAL METRICS      504

15.7.2      COMPANY VALUATION 504

15.8         BRAND/PRODUCT COMPARISON             505

15.9         COMPETITIVE SCENARIO             506

15.9.1      PRODUCT LAUNCHES & UPGRADES       506

15.9.2      DEALS  507

15.9.3      EXPANSIONS     509

16            COMPANY PROFILES      510

16.1         KEY PLAYERS     510

16.1.1      NVIDIA CORPORATION 510

16.1.1.1  Business overview 510

16.1.1.2  Products offered   511

16.1.1.3  Recent developments           512

16.1.1.3.1                Product launches  512

16.1.1.3.2                Deals      512

16.1.1.4  MnM view              515

16.1.1.4.1                Right to win           515

16.1.1.4.2                Strategic choices   515

16.1.1.4.3                Weaknesses & competitive threats     515

16.1.2      ILLUMINA, INC. 516

16.1.2.1  Business overview 516

16.1.2.2  Products offered   517

16.1.2.3  Recent developments           518

16.1.2.3.1                Product launches  518

16.1.2.3.2                Deals      519

16.1.2.4  MnM view              521

16.1.2.4.1                Right to win           521

16.1.2.4.2                Strategic choices   521

16.1.2.4.3                Weaknesses & competitive threats     521

16.1.3      RECURSION        522

16.1.3.1  Business overview 522

16.1.3.2  Products offered   523

16.1.3.3  Recent developments           523

16.1.3.3.1                Product launches  523

16.1.3.3.2                Deals      523

16.1.3.3.3                Expansions             525

16.1.3.3.4                Other developments             526

16.1.3.4  MnM view              526

16.1.3.4.1                Right to win           526

16.1.3.4.2                Strategic choices   526

16.1.3.4.3                Weaknesses & competitive threats     526

16.1.4      SCHRÖDINGER, INC.      527

16.1.4.1  Business overview 527

16.1.4.2  Products offered   528

16.1.4.3  Recent developments           529

16.1.4.3.1                Product upgrades 529

16.1.4.3.2                Deals      529

16.1.4.3.3                Other developments             531

16.1.4.4  MnM view              531

16.1.4.4.1                Right to win           531

16.1.4.4.2                Strategic choices   532

16.1.4.4.3                Weaknesses & competitive threats     532

16.1.5      BENEVOLENTAI               533

16.1.5.1  Business overview 533

16.1.5.2  Products offered   534

16.1.5.3  Recent developments           534

16.1.5.3.1                Deals      534

16.1.5.3.2                Other developments             535

16.1.5.4  MnM view              536

16.1.5.4.1                Right to win           536

16.1.5.4.2                Strategic choices   536

16.1.5.4.3                Weaknesses & competitive threats     536

16.1.6      DATA4CURE, INC.            537

16.1.6.1  Business overview 537

16.1.6.2  Products offered   537

16.1.6.3  Recent developments           538

16.1.6.3.1                Deals      538

16.1.7      QIAGEN                539

16.1.7.1  Business overview 539

16.1.7.2  Products offered   540

16.1.7.3  Recent developments           541

16.1.7.3.1                Product launches and enhancements                 541

16.1.7.3.2                Deals      541

16.1.8      INSILICO MEDICINE       543

16.1.8.1  Business overview 543

16.1.8.2  Products offered   543

16.1.8.3  Recent developments           544

16.1.8.3.1                Product launches, approvals, and enhancements                 544

16.1.8.3.2                Deals      545

16.1.8.3.3                Other developments             546

16.1.9      DNANEXUS, INC.               547

16.1.9.1  Business overview 547

16.1.9.2  Products offered   547

16.1.9.3  Recent developments           548

16.1.9.3.1                Deals      548

16.1.9.3.2                Other developments             550

16.1.10   TEMPUS               551

16.1.10.1                 Business overview 551

16.1.10.2                 Products offered   551

16.1.10.3                 Recent developments           552

16.1.10.3.1             Product approvals 552

16.1.10.3.2             Deals      552

16.1.10.3.3             Other developments             554

16.1.11   SOPHIA GENETICS          555

16.1.11.1                 Business overview 555

16.1.11.2                 Products offered   556

16.1.11.3                 Recent developments           557

16.1.11.3.1             Product launches  557

16.1.11.3.2             Deals      557

16.1.11.3.3             Other developments             559

16.1.12   PREDICTIVE ONCOLOGY             560

16.1.12.1                 Business overview 560

16.1.12.2                 Products offered   561

16.1.12.3                 Recent developments           561

16.1.12.3.1             Product launches  561

16.1.12.3.2             Deals      561

16.1.12.3.3             Expansions             562

16.1.13   DEEP GENOMICS             563

16.1.13.1                 Business overview 563

16.1.13.2                 Products offered   563

16.1.13.3                 Recent developments           564

16.1.13.3.1             Product launches  564

16.1.14   NUMEDII, INC.  565

16.1.14.1                 Business overview 565

16.1.14.2                 Products offered   565

16.1.15   XTALPI INC.       566

16.1.15.1                 Business overview 566

16.1.15.2                 Products offered   567

16.1.15.3                 Recent developments           568

16.1.15.3.1             Deals      568

16.1.16   IKTOS   570

16.1.16.1                 Business overview 570

16.1.16.2                 Products offered   570

16.1.16.3                 Recent developments           571

16.1.16.3.1             Product launches  571

16.1.16.3.2             Deals      571

16.1.16.3.3             Other developments             572

16.1.17   BPGBIO, INC.     573

16.1.17.1                 Business overview 573

16.1.17.2                 Products offered   573

16.1.17.3                 Recent developments           574

16.1.17.3.1             Product launches  574

16.1.17.3.2             Deals      574

16.1.17.3.3             Other developments             575

16.1.18   EUROFINS DISCOVERY 576

16.1.18.1                 Business overview 576

16.1.18.2                 Products offered   577

16.1.18.3                 Recent developments           577

16.1.18.3.1             Product launches  577

16.1.18.3.2             Deals      578

16.1.18.3.3             Expansions             579

16.2         OTHER PLAYERS              580

16.2.1      VERISIM LIFE     580

16.2.2      LIFEBIT BIOTECH INC.  580

16.2.3      VALO HEALTH  581

16.2.4      VERGE GENOMICS          581

16.2.5      LOGICA                582

16.2.6      AMERICAN CHEMICAL SOCIETY                583

16.2.7      AGANITHA AI INC.           584

17            APPENDIX           585

17.1         DISCUSSION GUIDE        585

17.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                592

17.3         CUSTOMIZATION OPTIONS        594

17.4         RELATED REPORTS         594

17.5         AUTHOR DETAILS           595

LIST OF TABLES

TABLE 1                AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS 55

TABLE 2                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD                57

TABLE 3                AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS  70

TABLE 4                AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT     71

TABLE 5                AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS           81

TABLE 6                INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN

AI IN BIOTECHNOLOGY MARKET, 2022−2025      82

TABLE 7                TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS 89

TABLE 8                AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 94

TABLE 9                FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM    99

TABLE 10              TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS,

BY KEY PLAYER, 2024 (USD)         100

TABLE 11              TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024)               101

TABLE 12              AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026                 101

TABLE 13              US ADJUSTED RECIPROCAL TARIFF RATES                 105

TABLE 14              JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015–2025   112

TABLE 15              TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2025              114

TABLE 16              REGULATORY SCENARIO OF NORTH AMERICA                 124

TABLE 17              REGULATORY SCENARIO OF EUROPE    125

TABLE 18              REGULATORY SCENARIO OF ASIA PACIFIC                 126

TABLE 19              REGULATORY SCENARIO OF LATIN AMERICA                 127

TABLE 20              REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 127

TABLE 21              TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             128

TABLE 22              TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 128

TABLE 23              TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 129

TABLE 24              TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             129

TABLE 25              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF

TOP THREE END USERS (%)        132

TABLE 26              KEY BUYING CRITERIA FOR TOP THREE END USERS   132

TABLE 27              UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET               133

TABLE 28              TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET        134

TABLE 29             AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)            136

TABLE 30             AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)            136

TABLE 31              AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,

2023–2029 (USD MILLION)            137

TABLE 32              AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,

2030–2035 (USD MILLION)            138

TABLE 33              AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,

2023–2029 (USD MILLION)            139

TABLE 34              AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,

2030–2035 (USD MILLION)            139

TABLE 35              AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,

2023–2029 (USD MILLION)            140

TABLE 36              AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,

2030–2035 (USD MILLION)            140

TABLE 37             AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,

2023–2029 (USD MILLION)            141

TABLE 38             AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,

2030–2035 (USD MILLION)            141

TABLE 39              CONSULTING SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)            142

TABLE 40              CONSULTING SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION)            142

TABLE 41              IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023–2029 (USD MILLION)                 143

TABLE 42              IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030–2035 (USD MILLION)                 143

TABLE 43             TRAINING AND EDUCATION SERVICES MARKET, BY REGION,

2023–2029 (USD MILLION)            144

TABLE 44             TRAINING AND EDUCATION SERVICES MARKET, BY REGION,

2030–2035 (USD MILLION)            144

TABLE 45              POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION,

2023–2029 (USD MILLION)            145

TABLE 46              AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030–2035 (USD MILLION) 146

TABLE 47              AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   148

TABLE 48              AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   148

TABLE 49              AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            149

TABLE 50              AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            150

TABLE 51              AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023–2029 (USD MILLION)            150

TABLE 52              AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030–2035 (USD MILLION)            150

TABLE 53              EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY        151

TABLE 54              DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 151

TABLE 55              DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 152

TABLE 56              DRUG DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)       152

TABLE 57              DRUG DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)       152

TABLE 58              MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,

2023–2029 (USD MILLION)            153

TABLE 59              MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION,

2030–2035 (USD MILLION)            153

TABLE 60              BIOMARKER DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)            154

TABLE 61              BIOMARKER DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)            154

TABLE 62              STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023–2029 (USD MILLION)                 155

TABLE 63              STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030–2035 (USD MILLION)                 155

TABLE 64              CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)            156

TABLE 65              CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)            157

TABLE 66             CLINICAL DEVELOPMENT MARKET, BY REGION, 2023–2029 (USD MILLION)            157

TABLE 67             CLINICAL DEVELOPMENT MARKET, BY REGION, 2030–2035 (USD MILLION)            158

TABLE 68              TRIAL DESIGN MARKET, BY REGION, 2023–2029 (USD MILLION) 158

TABLE 69              TRIAL DESIGN MARKET, BY REGION, 2030–2035 (USD MILLION) 159

TABLE 70              SITE SELECTION MARKET, BY REGION, 2023–2029 (USD MILLION)       159

TABLE 71              SITE SELECTION MARKET, BY REGION, 2030–2035 (USD MILLION)       160

TABLE 72              RECRUITMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 160

TABLE 73              RECRUITMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 161

TABLE 74              CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023–2029 (USD MILLION)          161

TABLE 75              CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030–2035 (USD MILLION)          162

TABLE 76              PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,

2023–2029 (USD MILLION)            162

TABLE 77              PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION,

2030–2035 (USD MILLION)            163

TABLE 78              MONITORING & DRUG ADHERENCE MARKET, BY REGION,

2023–2029 (USD MILLION)            163

TABLE 79              MONITORING & DRUG ADHERENCE MARKET, BY REGION,

2030–2035 (USD MILLION)            164

TABLE 80              REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,

2023–2029 (USD MILLION)            164

TABLE 81              REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION,

2030–2035 (USD MILLION)            165

TABLE 82              AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2029 (USD MILLION)            166

TABLE 83              AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030–2035 (USD MILLION)            166

TABLE 84              AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            167

TABLE 85              AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            167

TABLE 86              AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY REGION, 2023–2029 (USD MILLION)   168

TABLE 87              AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY REGION, 2030–2035 (USD MILLION)   168

TABLE 88             SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023–2029 (USD MILLION)            169

TABLE 89             SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030–2035 (USD MILLION)            169

TABLE 90              INVENTORY MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)          170

TABLE 91              INVENTORY MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)          170

TABLE 92              LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)          171

TABLE 93              LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)          171

TABLE 94              DEMAND FORECASTING MARKET, BY REGION, 2023–2029 (USD MILLION)            172

TABLE 95              DEMAND FORECASTING MARKET, BY REGION, 2030–2035 (USD MILLION)            172

TABLE 96              PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023–2029 (USD MILLION)          173

TABLE 97              PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030–2035 (USD MILLION)          173

TABLE 98              OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)                 174

TABLE 99              OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)                 174

TABLE 100            AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,

2023–2029 (USD MILLION)            175

TABLE 101            AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE,

2030–2035 (USD MILLION)            175

TABLE 102            AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,

2023–2029 (USD MILLION)            176

TABLE 103            AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION,

2030–2035 (USD MILLION)            176

TABLE 104          LAUNCH COORDINATION MARKET, BY REGION, 2023–2029 (USD MILLION)            177

TABLE 105          LAUNCH COORDINATION MARKET, BY REGION, 2030–2035 (USD MILLION)            177

TABLE 106            PATIENT ENGAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)            178

TABLE 107            PATIENT ENGAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)            178

TABLE 108          MARKETING OPERATIONS MARKET, BY REGION, 2023–2029 (USD MILLION)            179

TABLE 109          MARKETING OPERATIONS MARKET, BY REGION, 2030–2035 (USD MILLION)            179

TABLE 110            PREDICTIVE PRICING MARKET, BY REGION, 2023–2029 (USD MILLION)            180

TABLE 111            PREDICTIVE PRICING MARKET, BY REGION, 2030–2035 (USD MILLION)            180

TABLE 112            AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)            181

TABLE 113            AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)            181

TABLE 114            AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023–2029 (USD MILLION)            182

TABLE 115            AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030–2035 (USD MILLION)            182

TABLE 116            MEDICATION ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION)          183

TABLE 117            MEDICATION ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION)          183

TABLE 118            ADVERSE EVENT REPORTING MARKET, BY REGION, 2023–2029 (USD MILLION)          184

TABLE 119            ADVERSE EVENT REPORTING MARKET, BY REGION, 2030–2035 (USD MILLION)          184

TABLE 120            PATIENT MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)            185

TABLE 121            PATIENT MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)            185

TABLE 122            COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)          186

TABLE 123            COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)          186

TABLE 124            PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023–2029 (USD MILLION)          187

TABLE 125            PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030–2035 (USD MILLION)          187

TABLE 126            AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            188

TABLE 127            AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            188

TABLE 128            AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,

2023–2029 (USD MILLION)            189

TABLE 129            AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION,

2030–2035 (USD MILLION)            189

TABLE 130            RISK MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)       190

TABLE 131            RISK MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)       190

TABLE 132            COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)          191

TABLE 133            COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)          191

TABLE 134            SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)          192

TABLE 135            SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)          192

TABLE 136            OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)          193

TABLE 137            OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)          193

TABLE 138            AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            195

TABLE 139            AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            195

TABLE 140            AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,

2023–2029 (USD MILLION)            196

TABLE 141            AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,

2030–2035 (USD MILLION)            196

TABLE 142            AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)                 196

TABLE 143            AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)                 197

TABLE 144            PUBLIC CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 198

TABLE 145            PUBLIC CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 198

TABLE 146            PRIVATE CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)       199

TABLE 147            PRIVATE CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)       199

TABLE 148            MULTI CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 200

TABLE 149            MULTI CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 200

TABLE 150            HYBRID CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 201

TABLE 151            HYBRID CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 201

TABLE 152            AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)                 202

TABLE 153            AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)                 203

TABLE 154            AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)            205

TABLE 155            AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)            205

TABLE 156            AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2029 (USD MILLION)            206

TABLE 157            AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030–2035 (USD MILLION)            207

TABLE 158            AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2029 (USD MILLION)            208

TABLE 159            AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030–2035 (USD MILLION)            208

TABLE 160            AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023–2029 (USD MILLION)            209

TABLE 161            AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030–2035 (USD MILLION)            209

TABLE 162            AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2029 (USD MILLION)            210

TABLE 163            AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030–2035 (USD MILLION)            211

TABLE 164            AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY REGION, 2023–2029 (USD MILLION)   212

TABLE 165            AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY REGION, 2030–2035 (USD MILLION)   212

TABLE 166            AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION)            214

TABLE 167            AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION)            214

TABLE 168            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2023–2029 (USD MILLION)            216

TABLE 169            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2030–2035 (USD MILLION)            216

TABLE 170            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            216

TABLE 171            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            217

TABLE 172            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            217

TABLE 173            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            218

TABLE 174            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            218

TABLE 175            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            219

TABLE 176            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 219

TABLE 177            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 219

TABLE 178            NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            220

TABLE 179            NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            220

TABLE 180            NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            221

TABLE 181            NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            221

TABLE 182            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            222

TABLE 183            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            222

TABLE 184            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 223

TABLE 185            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 223

TABLE 186            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   223

TABLE 187            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   224

TABLE 188            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)                 224

TABLE 189            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)                 225

TABLE 190            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)                 225

TABLE 191            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)                 225

TABLE 192            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 226

TABLE 193            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 226

TABLE 194            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            226

TABLE 195            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            227

TABLE 196            US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     228

TABLE 197            US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     228

TABLE 198            US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            228

TABLE 199            US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            229

TABLE 200            US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   229

TABLE 201            US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   230

TABLE 202            US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            230

TABLE 203            US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            230

TABLE 204            US: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)       231

TABLE 205            US: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)       231

TABLE 206            US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                231

TABLE 207            US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                232

TABLE 208            US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2023–2029 (USD MILLION)         232

TABLE 209            US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2030–2035 (USD MILLION)         233

TABLE 210            US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 233

TABLE 211            US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 234

TABLE 212            US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)            234

TABLE 213            US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)            235

TABLE 214            US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            235

TABLE 215            US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            236

TABLE 216            US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            236

TABLE 217            US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            236

TABLE 218            US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 237

TABLE 219            US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 237

TABLE 220            US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)                237

TABLE 221            US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)                238

TABLE 222            CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            238

TABLE 223            CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            239

TABLE 224            CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            239

TABLE 225            CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            239

TABLE 226            CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            240

TABLE 227            CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            240

TABLE 228            CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         241

TABLE 229            CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         241

TABLE 230            CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            241

TABLE 231            CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            242

TABLE 232            CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)         242

TABLE 233            CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)         243

TABLE 234            CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            243

TABLE 235            CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            244

TABLE 236            CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 244

TABLE 237            CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 245

TABLE 238            CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                245

TABLE 239            CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                246

TABLE 240            CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            246

TABLE 241            CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            247

TABLE 242            CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            247

TABLE 243            CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            247

TABLE 244            CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2023–2029 (USD MILLION)         248

TABLE 245            CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2030–2035 (USD MILLION)         248

TABLE 246            CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            248

TABLE 247            CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            249

TABLE 248            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2023–2029 (USD MILLION)            250

TABLE 249            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2030–2035 (USD MILLION)            250

TABLE 250            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            251

TABLE 251            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            251

TABLE 252            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            251

TABLE 253            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            252

TABLE 254            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            252

TABLE 255            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            253

TABLE 256            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         253

TABLE 257            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         253

TABLE 258            EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            254

TABLE 259            EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            254

TABLE 260            EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)         254

TABLE 261            EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)         255

TABLE 262            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            255

TABLE 263            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            256

TABLE 264            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 256

TABLE 265            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 257

TABLE 266            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                257

TABLE 267            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                258

TABLE 268            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            258

TABLE 269            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            259

TABLE 270            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            259

TABLE 271            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            259

TABLE 272            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2023–2029 (USD MILLION)         260

TABLE 273            EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2030–2035 (USD MILLION)         260

TABLE 274            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            260

TABLE 275            EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            261

TABLE 276            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            262

TABLE 277            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            262

TABLE 278            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            262

TABLE 279            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            263

TABLE 280            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            263

TABLE 281            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            264

TABLE 282            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         264

TABLE 283            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)       264

TABLE 284            GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)                265

TABLE 285            GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)                265

TABLE 286            GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            265

TABLE 287            GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            266

TABLE 288            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 266

TABLE 289            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 267

TABLE 290            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2023–2029 (USD MILLION)         267

TABLE 291            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2030–2035 (USD MILLION)         268

TABLE 292            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)         268

TABLE 293            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)         269

TABLE 294            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            269

TABLE 295            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            270

TABLE 296            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            270

TABLE 297            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            270

TABLE 298            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2023–2029 (USD MILLION)         271

TABLE 299            GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2030–2035 (USD MILLION)         271

TABLE 300            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            271

TABLE 301            GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            272

TABLE 302            UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     272

TABLE 303            UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     273

TABLE 304            UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            273

TABLE 305            UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            273

TABLE 306            UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   274

TABLE 307            UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   274

TABLE 308            UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            275

TABLE 309            UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            275

TABLE 310            UK: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)       275

TABLE 311            UK: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)       276

TABLE 312            UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                276

TABLE 313            UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                277

TABLE 314            UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2023–2029 (USD MILLION)         277

TABLE 315            UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2030–2035 (USD MILLION)         278

TABLE 316            UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 278

TABLE 317            UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 279

TABLE 318            UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                279

TABLE 319            UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                280

TABLE 320            UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            280

TABLE 321            UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            281

TABLE 322            UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            281

TABLE 323            UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            281

TABLE 324            UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 282

TABLE 325            UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 282

TABLE 326            UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)                282

TABLE 327            UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)                283

TABLE 328            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            284

TABLE 329            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            284

TABLE 330            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            284

TABLE 331            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            285

TABLE 332            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            285

TABLE 333            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            286

TABLE 334            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         286

TABLE 335            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         286

TABLE 336            FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            287

TABLE 337            FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            287

TABLE 338            FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)         287

TABLE 339            FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)         288

TABLE 340            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            288

TABLE 341            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            289

TABLE 342            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 289

TABLE 343            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 290

TABLE 344            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                290

TABLE 345            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                291

TABLE 346            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            291

TABLE 347            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            292

TABLE 348            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            292

TABLE 349            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            292

TABLE 350            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 293

TABLE 351            FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 293

TABLE 352            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            293

TABLE 353            FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            294

TABLE 354            ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     295

TABLE 355            ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     295

TABLE 356            ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            295

TABLE 357            ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            296

TABLE 358            ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   296

TABLE 359            ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   297

TABLE 360            ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            297

TABLE 361            ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            297

TABLE 362            ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            298

TABLE 363            ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            298

TABLE 364            ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                298

TABLE 365            ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                299

TABLE 366            ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2023–2029 (USD MILLION)         299

TABLE 367            ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2030–2035 (USD MILLION)         300

TABLE 368            ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 300

TABLE 369            ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 301

TABLE 370            ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                301

TABLE 371            ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                302

TABLE 372            ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            302

TABLE 373            ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            303

TABLE 374            ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            303

TABLE 375            ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            303

TABLE 376            ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 304

TABLE 377            ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 304

TABLE 378            ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)     304

TABLE 379            ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)     305

TABLE 380            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     305

TABLE 381            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     306

TABLE 382            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            306

TABLE 383            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            306

TABLE 384            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   307

TABLE 385            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   307

TABLE 386            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         308

TABLE 387            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         308

TABLE 388            SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            308

TABLE 389            SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            309

TABLE 390            SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                309

TABLE 391            SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                310

TABLE 392            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            310

TABLE 393            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            311

TABLE 394            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 311

TABLE 395            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 312

TABLE 396            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                312

TABLE 397            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                313

TABLE 398            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            313

TABLE 399            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            314

TABLE 400            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            314

TABLE 401            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            314

TABLE 402            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 315

TABLE 403            SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 315

TABLE 404            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)     315

TABLE 405            SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)     316

TABLE 406            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            317

TABLE 407            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            317

TABLE 408            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)                 317

TABLE 409            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)                 318

TABLE 410            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            318

TABLE 411            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            319

TABLE 412            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 319

TABLE 413            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 319

TABLE 414            REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            320

TABLE 415            REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            320

TABLE 416            REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            320

TABLE 417            REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            321

TABLE 418            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            321

TABLE 419            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            322

TABLE 420            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 322

TABLE 421            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 323

TABLE 422            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   323

TABLE 423            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   324

TABLE 424            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)                 324

TABLE 425            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)                 325

TABLE 426            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)                 325

TABLE 427            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)                 325

TABLE 428            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 326

TABLE 429            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 326

TABLE 430            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            326

TABLE 431            REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            327

TABLE 432            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2023–2029 (USD MILLION)            328

TABLE 433            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2030–2035 (USD MILLION)            329

TABLE 434            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            329

TABLE 435            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            329

TABLE 436            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            330

TABLE 437            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            330

TABLE 438            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            331

TABLE 439            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            331

TABLE 440            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            332

TABLE 441            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            332

TABLE 442            ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)                332

TABLE 443            ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)                333

TABLE 444            ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            333

TABLE 445            ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            334

TABLE 446            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 334

TABLE 447            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 335

TABLE 448            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2023–2029 (USD MILLION)         335

TABLE 449            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2030–2035 (USD MILLION)         336

TABLE 450            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)         336

TABLE 451            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)         337

TABLE 452            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            337

TABLE 453            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            338

TABLE 454            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            338

TABLE 455            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            338

TABLE 456            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2023–2029 (USD MILLION)         339

TABLE 457            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2030–2035 (USD MILLION)         339

TABLE 458            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            339

TABLE 459            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            340

TABLE 460            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     341

TABLE 461            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     341

TABLE 462            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            341

TABLE 463            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            342

TABLE 464            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   342

TABLE 465            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   343

TABLE 466            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         343

TABLE 467            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         343

TABLE 468            JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            344

TABLE 469            JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            344

TABLE 470            JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                344

TABLE 471            JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                345

TABLE 472            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            345

TABLE 473            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            346

TABLE 474            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 346

TABLE 475            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 347

TABLE 476            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                347

TABLE 477            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                348

TABLE 478            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            348

TABLE 479            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            349

TABLE 480            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            349

TABLE 481            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            349

TABLE 482            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 350

TABLE 483            JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 350

TABLE 484            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            350

TABLE 485            JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            351

TABLE 486            CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     352

TABLE 487            CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     352

TABLE 488            CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            352

TABLE 489            CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            353

TABLE 490            CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   353

TABLE 491            CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   354

TABLE 492            CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         354

TABLE 493            CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         354

TABLE 494            CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            355

TABLE 495            CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            355

TABLE 496            CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                355

TABLE 497            CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                356

TABLE 498            CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            356

TABLE 499            CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            357

TABLE 500            CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 357

TABLE 501            CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 358

TABLE 502            CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                358

TABLE 503            CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                359

TABLE 504            CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            359

TABLE 505            CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            360

TABLE 506            CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            360

TABLE 507            CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            360

TABLE 508            CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 361

TABLE 509            CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 361

TABLE 510            CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            361

TABLE 511            CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            362

TABLE 512            INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)     362

TABLE 513            INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)     363

TABLE 514            INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            363

TABLE 515            INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            363

TABLE 516            INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)   364

TABLE 517            INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)   364

TABLE 518            INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)            365

TABLE 519            INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)            365

TABLE 520            INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            365

TABLE 521            INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            366

TABLE 522            INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                366

TABLE 523            INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                367

TABLE 524            INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2023–2029 (USD MILLION)         367

TABLE 525            INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN,

BY TYPE, 2030–2035 (USD MILLION)         368

TABLE 526            INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 368

TABLE 527            INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 369

TABLE 528            INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                369

TABLE 529            INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                370

TABLE 530            INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            370

TABLE 531            INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            371

TABLE 532            INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            371

TABLE 533            INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            371

TABLE 534            INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 372

TABLE 535            INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 372

TABLE 536            INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)     372

TABLE 537            INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)     373

TABLE 538            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            374

TABLE 539            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            374

TABLE 540            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            374

TABLE 541            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            375

TABLE 542            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            375

TABLE 543            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            376

TABLE 544            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 376

TABLE 545            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 376

TABLE 546            SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)                377

TABLE 547            SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)                377

TABLE 548            SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            377

TABLE 549            SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            378

TABLE 550            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            378

TABLE 551            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            379

TABLE 552            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2023–2029 (USD MILLION)         379

TABLE 553            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2030–2035 (USD MILLION)         380

TABLE 554            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   380

TABLE 555            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   381

TABLE 556            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            381

TABLE 557            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            382

TABLE 558            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            382

TABLE 559            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            382

TABLE 560            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 383

TABLE 561            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 383

TABLE 562            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            383

TABLE 563            SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            384

TABLE 564            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            384

TABLE 565            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            385

TABLE 566            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            385

TABLE 567            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            385

TABLE 568            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            386

TABLE 569            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            386

TABLE 570            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         387

TABLE 571            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         387

TABLE 572            AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)                387

TABLE 573            AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)                388

TABLE 574            AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            388

TABLE 575            AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            389

TABLE 576            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 389

TABLE 577            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 390

TABLE 578            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2023–2029 (USD MILLION)         390

TABLE 579            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2030–2035 (USD MILLION)         391

TABLE 580            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)         391

TABLE 581            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)         392

TABLE 582            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            392

TABLE 583            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            393

TABLE 584            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            393

TABLE 585            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            393

TABLE 586            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2023–2029 (USD MILLION)         394

TABLE 587            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE, 2030–2035 (USD MILLION)         394

TABLE 588            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            394

TABLE 589            AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            395

TABLE 590            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            396

TABLE 591            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            396

TABLE 592            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)                 396

TABLE 593            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)                 397

TABLE 594            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            397

TABLE 595            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            398

TABLE 596            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 398

TABLE 597            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 398

TABLE 598            REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            399

TABLE 599            REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            399

TABLE 600            REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            399

TABLE 601            REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            400

TABLE 602            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            400

TABLE 603            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            401

TABLE 604            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 401

TABLE 605            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 402

TABLE 606            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   402

TABLE 607            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   403

TABLE 608            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)                 403

TABLE 609            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)                 404

TABLE 610            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)                 404

TABLE 611            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)                 404

TABLE 612            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 405

TABLE 613            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 405

TABLE 614            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            405

TABLE 615            REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            406

TABLE 616            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2023–2029 (USD MILLION)            406

TABLE 617            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,

2030–2035 (USD MILLION)            407

TABLE 618            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            407

TABLE 619            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            407

TABLE 620            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            408

TABLE 621            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            408

TABLE 622            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            409

TABLE 623            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            409

TABLE 624            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 410

TABLE 625            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 410

TABLE 626            LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)         410

TABLE 627            LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)         411

TABLE 628            LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            411

TABLE 629            LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            412

TABLE 630            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            412

TABLE 631            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            413

TABLE 632            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2023–2029 (USD MILLION)         413

TABLE 633            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL,

BY TYPE, 2030–2035 (USD MILLION)         414

TABLE 634            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   414

TABLE 635            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   415

TABLE 636            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)                 415

TABLE 637            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)                 416

TABLE 638            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            416

TABLE 639            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            416

TABLE 640            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 417

TABLE 641            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 417

TABLE 642            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            417

TABLE 643            LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            418

TABLE 644            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            419

TABLE 645            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            419

TABLE 646            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            419

TABLE 647            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            420

TABLE 648            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            420

TABLE 649            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            421

TABLE 650            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         421

TABLE 651            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         421

TABLE 652            BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            422

TABLE 653            BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            422

TABLE 654            BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                422

TABLE 655            BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                423

TABLE 656            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            423

TABLE 657            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            424

TABLE 658            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 424

TABLE 659            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 425

TABLE 660            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                425

TABLE 661            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                426

TABLE 662            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            426

TABLE 663            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            427

TABLE 664            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            427

TABLE 665            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            427

TABLE 666            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 428

TABLE 667            BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 428

TABLE 668            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            428

TABLE 669            BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            429

TABLE 670            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            429

TABLE 671            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            430

TABLE 672            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            430

TABLE 673            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            430

TABLE 674            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            431

TABLE 675            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            431

TABLE 676            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2023–2029 (USD MILLION)         432

TABLE 677            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT,

BY TYPE, 2030–2035 (USD MILLION)         432

TABLE 678            MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)            432

TABLE 679            MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)            433

TABLE 680            MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)         433

TABLE 681            MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)         434

TABLE 682            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            434

TABLE 683            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            435

TABLE 684            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                 435

TABLE 685            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                 436

TABLE 686            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)                436

TABLE 687            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)                437

TABLE 688            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2023–2029 (USD MILLION)            437

TABLE 689            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE,

2030–2035 (USD MILLION)            438

TABLE 690            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            438

TABLE 691            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            438

TABLE 692            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 439

TABLE 693            MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 439

TABLE 694            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            439

TABLE 695            MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            440

TABLE 696            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            440

TABLE 697            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            441

TABLE 698            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 441

TABLE 699            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 442

TABLE 700            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            442

TABLE 701            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            443

TABLE 702            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)         443

TABLE 703            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)         443

TABLE 704            REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            444

TABLE 705            REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            444

TABLE 706            REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            445

TABLE 707            REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            445

TABLE 708            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)         446

TABLE 709            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)         446

TABLE 710            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                447

TABLE 711            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                447

TABLE 712            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)            447

TABLE 713            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)            448

TABLE 714            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE,

BY TYPE, 2023–2029 (USD MILLION)         448

TABLE 715            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE,

BY TYPE, 2030–2035 (USD MILLION)         449

TABLE 716            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET,

BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)        449

TABLE 717            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET,

BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)        449

TABLE 718            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)         450

TABLE 719            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)         450

TABLE 720            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            450

TABLE 721            REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            451

TABLE 722            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION,

2023–2029 (USD MILLION)            452

TABLE 723            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION,

2030–2035 (USD MILLION)            452

TABLE 724            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            452

TABLE 725            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            453

TABLE 726            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 453

TABLE 727            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 454

TABLE 728            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            454

TABLE 729            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            455

TABLE 730            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)         455

TABLE 731            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)         455

TABLE 732            MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            456

TABLE 733            MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            456

TABLE 734            MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            457

TABLE 735            MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            457

TABLE 736            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)         458

TABLE 737            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)         458

TABLE 738            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                459

TABLE 739            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                459

TABLE 740            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)            459

TABLE 741            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)            460

TABLE 742            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE,

BY TYPE, 2023–2029 (USD MILLION)         460

TABLE 743            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE,

BY TYPE, 2030–2035 (USD MILLION)         461

TABLE 744            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 461

TABLE 745            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 461

TABLE 746            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)         462

TABLE 747            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)         462

TABLE 748            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            462

TABLE 749            MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            463

TABLE 750            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2023–2029 (USD MILLION)            465

TABLE 751            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,

2030–2035 (USD MILLION)            465

TABLE 752            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2023–2029 (USD MILLION)            465

TABLE 753            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,

2030–2035 (USD MILLION)            466

TABLE 754            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2023–2029 (USD MILLION)            466

TABLE 755            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,

2030–2035 (USD MILLION)            467

TABLE 756            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 467

TABLE 757            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 467

TABLE 758            GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            468

TABLE 759            GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            468

TABLE 760            GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2023–2029 (USD MILLION)            468

TABLE 761            GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE,

2030–2035 (USD MILLION)            469

TABLE 762            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)            469

TABLE 763            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)            470

TABLE 764            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 470

TABLE 765            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 471

TABLE 766            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)   471

TABLE 767            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)   472

TABLE 768            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)                 472

TABLE 769            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)                 473

TABLE 770            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2023–2029 (USD MILLION)            473

TABLE 771            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2030–2035 (USD MILLION)            473

TABLE 772            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 474

TABLE 773            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 474

TABLE 774            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2023–2029 (USD MILLION)            474

TABLE 775            GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER,

2030–2035 (USD MILLION)            475

TABLE 776            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)            476

TABLE 777            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)            476

TABLE 778            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 476

TABLE 779            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 477

TABLE 780            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)            477

TABLE 781            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)            478

TABLE 782            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)         478

TABLE 783            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)         478

TABLE 784            REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE,

2023–2029 (USD MILLION)            479

TABLE 785            REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE,

2030–2035 (USD MILLION)            479

TABLE 786            REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)                 480

TABLE 787            REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)                 480

TABLE 788            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)         481

TABLE 789            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)         481

TABLE 790            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)                482

TABLE 791            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)                482

TABLE 792            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE,

2023–2029 (USD MILLION)            482

TABLE 793            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE,

2030–2035 (USD MILLION)            483

TABLE 794            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)       483

TABLE 795            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)       484

TABLE 796            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET,

BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)        484

TABLE 797            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET,

BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)        484

TABLE 798            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR

CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)                 485

TABLE 799            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR

CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)                 485

TABLE 800            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)            485

TABLE 801            REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)            486

TABLE 802            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, JANUARY 2022–NOVEMBER 2025               487

TABLE 803            AI IN BIOTECHNOLOGY MARKET: DEGREE OF COMPETITION 491

TABLE 804            AI IN BIOTECHNOLOGY: REGION FOOTPRINT                 496

TABLE 805            AI IN BIOTECHNOLOGY MARKET: COMPONENT FOOTPRINT       497

TABLE 806            AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT       498

TABLE 807            AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT       499

TABLE 808            AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS  502

TABLE 809            AI IN BIOTECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING, FUNCTION, END USER, AND REGION                 503

TABLE 810            AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES,

JANUARY 2022–NOVEMBER 2025                 506

TABLE 811            AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2022–NOVEMBER 2025                 507

TABLE 812            AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025                 509

TABLE 813            NVIDIA CORPORATION: COMPANY OVERVIEW                 510

TABLE 814            NVIDIA CORPORATION: PRODUCTS OFFERED                 511

TABLE 815            NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025               512

TABLE 816            NVIDIA CORPORATION: DEALS, JANUARY 2022−NOVEMBER 2025  512

TABLE 817            ILLUMINA, INC.: COMPANY OVERVIEW 516

TABLE 818            ILLUMINA, INC.: PRODUCTS OFFERED  517

TABLE 819            ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025               518

TABLE 820            ILLUMINA, INC.: DEALS, JANUARY 2022−NOVEMBER 2025  519

TABLE 821            RECURSION: COMPANY OVERVIEW         522

TABLE 822            RECURSION: PRODUCTS OFFERED          523

TABLE 823            RECURSION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025  523

TABLE 824            RECURSION: DEALS, JANUARY 2022−NOVEMBER 2025  523

TABLE 825            RECURSION: EXPANSIONS, JANUARY 2022−NOVEMBER 2025  525

TABLE 826            RECURSION: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               526

TABLE 827            SCHRÖDINGER, INC.: COMPANY OVERVIEW                 527

TABLE 828            SCHRÖDINGER, INC.: PRODUCTS OFFERED                 528

TABLE 829            SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2022−NOVEMBER 2025               529

TABLE 830            SCHRÖDINGER, INC.: DEALS, JANUARY 2022−NOVEMBER 2025  529

TABLE 831            SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               531

TABLE 832            BENEVOLENTAI: COMPANY OVERVIEW                 533

TABLE 833            BENEVOLENTAI: PRODUCTS OFFERED 534

TABLE 834            BENEVOLENTAI: DEALS, JANUARY 2022−NOVEMBER 2025  534

TABLE 835            BENEVOLENTAI: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               535

TABLE 836            DATA4CURE, INC.: COMPANY OVERVIEW                 537

TABLE 837            DATA4CURE, INC.: PRODUCTS OFFERED                 537

TABLE 838            DATA4CURE, INC.: DEALS, JANUARY 2022–NOVEMBER 2025               538

TABLE 839            QIAGEN: COMPANY OVERVIEW 539

TABLE 840            QIAGEN: PRODUCTS OFFERED 540

TABLE 841            QIAGEN: PRODUCT LAUNCHES AND ENHANCEMENTS,

JANUARY 2022−NOVEMBER 2025               541

TABLE 842            QIAGEN: DEALS, JANUARY 2022−NOVEMBER 2025        541

TABLE 843            INSILICO MEDICINE: COMPANY OVERVIEW                 543

TABLE 844            INSILICO MEDICINE: PRODUCTS OFFERED                 543

TABLE 845            INSILICO MEDICINE: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2022–NOVEMBER 2025        544

TABLE 846            INSILICO MEDICINE: DEALS, JANUARY 2022–NOVEMBER 2025               545

TABLE 847            INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025                 546

TABLE 848            DNANEXUS, INC.: COMPANY OVERVIEW                 547

TABLE 849            DNANEXUS, INC.: PRODUCTS OFFERED                 547

TABLE 850            DNANEXUS, INC.: DEALS, JANUARY 2022−NOVEMBER 2025  548

TABLE 851            DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               550

TABLE 852            TEMPUS: COMPANY OVERVIEW                551

TABLE 853            TEMPUS: PRODUCTS OFFERED 551

TABLE 854            TEMPUS: PRODUCT APPROVALS, JANUARY 2022–NOVEMBER 2025    552

TABLE 855            TEMPUS: DEALS, JANUARY 2022−NOVEMBER 2025        552

TABLE 856            TEMPUS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025  554

TABLE 857            SOPHIA GENETICS: COMPANY OVERVIEW                 555

TABLE 858            SOPHIA GENETICS: PRODUCTS OFFERED                 556

TABLE 859            SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025               557

TABLE 860            SOPHIA GENETICS: DEALS, JANUARY 2022−NOVEMBER 2025  557

TABLE 861            SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               559

TABLE 862            PREDICTIVE ONCOLOGY: COMPANY OVERVIEW          560

TABLE 863            PREDICTIVE ONCOLOGY: PRODUCTS OFFERED                 561

TABLE 864            PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025     561

TABLE 865            PREDICTIVE ONCOLOGY: DEALS, JANUARY 2022−NOVEMBER 2025  561

TABLE 866            PREDICTIVE ONCOLOGY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025               562

TABLE 867            DEEP GENOMICS: COMPANY OVERVIEW                 563

TABLE 868            DEEP GENOMICS: PRODUCTS OFFERED                 563

TABLE 869            DEEP GENOMICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025               564

TABLE 870            NUMEDII, INC.: COMPANY OVERVIEW   565

TABLE 871            NUMEDII, INC.: PRODUCTS OFFERED    565

TABLE 872            XTALPI INC.: COMPANY OVERVIEW        566

TABLE 873            XTALPI INC.: PRODUCTS OFFERED         567

TABLE 874            XTALPI INC.: DEALS, JANUARY 2022−NOVEMBER 2025  568

TABLE 875            IKTOS: COMPANY OVERVIEW    570

TABLE 876            IKTOS: PRODUCTS OFFERED     570

TABLE 877            IKTOS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025  571

TABLE 878            IKTOS: DEALS, JANUARY 2022−NOVEMBER 2025                 571

TABLE 879            IKTOS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025  572

TABLE 880            BPGBIO, INC.: COMPANY OVERVIEW      573

TABLE 881            BPGBIO, INC.: PRODUCTS OFFERED       573

TABLE 882            BPGBIO, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025  574

TABLE 883            BPGBIO, INC.: DEALS, JANUARY 2022−NOVEMBER 2025  574

TABLE 884            BPGBIO, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025               575

TABLE 885            EUROFINS DISCOVERY: COMPANY OVERVIEW                 576

TABLE 886            EUROFINS DISCOVERY: PRODUCTS OFFERED                 577

TABLE 887            EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025               577

TABLE 888            EUROFINS DISCOVERY: DEALS, JANUARY 2022−NOVEMBER 2025  578

TABLE 889            EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025  579

TABLE 890            VERISIM LIFE: COMPANY OVERVIEW      580

TABLE 891            LIFEBIT BIOTECH INC.: COMPANY OVERVIEW                 580

TABLE 892            VALO HEALTH: COMPANY OVERVIEW   581

TABLE 893            VERGE GENOMICS: COMPANY OVERVIEW                 581

TABLE 894            LOGICA: COMPANY OVERVIEW 582

TABLE 895            AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW          583

TABLE 896            AGANITHA AI INC.: COMPANY OVERVIEW                 584

LIST OF FIGURES

FIGURE 1              AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE    54

FIGURE 2              AI IN BIOTECHNOLOGY MARKET: YEARS CONSIDERED    56

FIGURE 3              RESEARCH DESIGN         59

FIGURE 4              PRIMARY SOURCES         62

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE):

BY COMPANY, DESIGNATION, AND REGION       64

FIGURE 6              MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS            65

FIGURE 7              TOP-DOWN APPROACH                66

FIGURE 8              AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS   67

FIGURE 9              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 68

FIGURE 10            DATA TRIANGULATION                69

FIGURE 11           AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2025 VS. 2035 (USD MILLION)      72

FIGURE 12            AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2025 VS. 2035 (USD MILLION)             73

FIGURE 13            AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,

2025 VS. 2035 (USD MILLION)      73

FIGURE 14            AI IN BIOTECHNOLOGY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)      74

FIGURE 15            AI IN BIOTECHNOLOGY MARKET: REGIONAL SNAPSHOT          75

FIGURE 16            FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT FUNDING TO DRIVE MARKET                 76

FIGURE 17            NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET

DURING STUDY PERIOD               77

FIGURE 18            END-TO-END SOLUTIONS AND US COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024        78

FIGURE 19            INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD         79

FIGURE 20            EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES

FROM 2025 TO 2035          79

FIGURE 21            AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          80

FIGURE 22            EVOLUTION OF AI IN BIOTECHNOLOGY MARKET               93

FIGURE 23            AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 94

FIGURE 24            AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS              96

FIGURE 25            AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS            98

FIGURE 26            TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           102

FIGURE 27            AI IN BIOTECHNOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO           103

FIGURE 28            AI IN BIOTECHNOLOGY MARKET: PATENT PUBLICATION TRENDS, 2015–2025            111

FIGURE 29            JURISDICTION AND TOP APPLICANT ANALYSIS, 2015–2025              111

FIGURE 30            AI IN BIOTECHNOLOGY MARKET: PATENT ANALYSIS,

JANUARY 2015–JANUARY 2025     113

FIGURE 31            MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS      118

FIGURE 32            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS     131

FIGURE 33            KEY BUYING CRITERIA FOR TOP THREE END USERS   132

FIGURE 34            NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS, 2019–2023        149

FIGURE 35            NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT       215

FIGURE 36            ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT          328

FIGURE 37            REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET,

2020–2024 (USD BILLION)             490

FIGURE 38            MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)                491

FIGURE 39            RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)           493

FIGURE 40            AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       494

FIGURE 41            AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT       495

FIGURE 42            AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX

(START-UPS/SMES), 2024               501

FIGURE 43            EV/EBITDA OF KEY VENDORS   504

FIGURE 44            YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF

AI IN BIOTECHNOLOGY SOLUTION VENDORS  504

FIGURE 45            AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     505

FIGURE 46            NVIDIA CORPORATION: COMPANY SNAPSHOT                 511

FIGURE 47            ILLUMINA, INC.: COMPANY SNAPSHOT 517

FIGURE 48            RECURSION: COMPANY SNAPSHOT        522

FIGURE 49            SCHRÖDINGER, INC.: COMPANY SNAPSHOT                 528

FIGURE 50            BENEVOLENTAI: COMPANY SNAPSHOT                 533

FIGURE 51            QIAGEN: COMPANY SNAPSHOT                 540

FIGURE 52            SOPHIA GENETICS: COMPANY SNAPSHOT                 556

FIGURE 53            PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT          560

FIGURE 54            XTALPI INC.: COMPANY SNAPSHOT        567

FIGURE 55            EUROFINS DISCOVERY: COMPANY SNAPSHOT                 576

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧